行情

IDXG

IDXG

Interpace
NASDAQ

实时行情|Nasdaq Last Sale

0.8319
+0.0206
+2.54%
已收盘, 16:00 09/16 EDT
开盘
0.8100
昨收
0.8113
最高
0.9000
最低
0.7846
成交量
200
成交额
--
52周最高
1.780
52周最低
0.6727
市值
3,177.53万
市盈率(TTM)
-1.6153
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

IDXG 新闻

  • 美交通部宣布首批自动驾驶研究补助金去向 三州入围
  • TechWeb.3小时前
  • 亚马逊被曝“做手脚”推销其高利润率产品
  • 澎湃新闻.3小时前
  • 美联储内部严重分歧或令未来政策前景更扑朔迷离
  • 汇通网.3小时前
  • 沙特准备动用家底 但“最后一道防线”可能面临失守
  • 汇通网.3小时前

更多

所属板块

商业支持服务
+0.59%
专业与商业服务
+0.19%

热门股票

名称
价格
涨跌幅

IDXG 简况

Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer.
展开

Webull提供Interpace Diagnostics Group Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。